Table 2

Rate of evidence-based T2D pharmacotherapy in MASH across race and ethnicities (n=767)

OutcomeLatino/a/x
n=39
NL Black
n=101
NL White
n=627
EBP17 (43.6%)35 (34.7%)214 (34.1%)
 GLP-1RA alone13 (33.3%)32 (31.7%)176 (28.1%)
 Pioglitazone alone1 (2.6%)2 (2.0%)21 (3.3%)
 Both GLP-1RA and pioglitazone3 (7.7%)1 (1.0%)17 (2.7%)
  • EBP, evidence-based T2D pharmacotherapy (prescription for pioglitazone and/or GLP-1RA; GLP-1RA, glucagon-like peptide-1 receptor agonist; MASH, metabolic dysfunction-associated steatohepatitis; NL, non-Latino/a/x; T2D, type 2 diabetes.